Amgen's D-mab beats Fosamax in trial

In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Fosamax. D-mab, as it's known, showed greater improvement in bone mineral density in the hip and spine compared to Fosamax. "The novel means by which denosumab inhibits osteoclast-mediated bone breakdown shows the promise of RANK Ligand inhibition," said Javier San Martin, Global Development Lead for the denosumab osteoporosis program.

- see Amgen's release
- read the report for more

Suggested Articles

The update, which could come as soon as tomorrow, may shed light on how the front-runner vaccine fared in early clinical trials. 

Pfizer has signed up for a new three-year deal, with the option for this to be extended to five years, with CRO Syneos Health.

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…